Abstract
Overview
Introduction
The influenza vaccine market, sized at approximately $2.2 billion in 2006,
yields many challenges. Demand is highly variable, and only large players are
able to cope with the need for annual updates and the costly manufacturing
process. However, driven by the increasing pandemic threat, the market is
growing fast and predicted to more than double in size by 2016.
Scope
- Strategic analysis of the current influenza market across the US, Japan,
France, Germany, Italy, Spain and the UK and of key companies in the sector
- Thorough assessment of underlying commercial and clinical influencers
shaping the influenza vaccine market
- Patient-based forecasts for the influenza vaccine market taking into
account recommended vaccination groups and coverage rates in the 7 major
markets
- In-depth comparative analysis of both seasonal and pandemic influenza
vaccine pipeline candidates and discussion of their future potential
Report Highlights
The demand for influenza vaccines is highly variable and the time window for
the vaccination is limited to just a few months per year. This, in combination
with the need for annual updates and the long planning cycles required due to
the lengthy egg-based manufacturing process, makes the flu vaccine market a
highly challenging sector.
The pandemic threat has acted as an important driver for the seasonal vaccine
market. Rising public awareness of influenza has increased the demand for
seasonal vaccination. Government funding provided for pandemic research is
also benefiting seasonal vaccine development through technology transfer.
With Novartis' cell-based Optaflu currently awaiting EU approval and
ProteinSciences' baculovirus-based FluBlØk in phase III, new production
techniques available are shaping up to change market dynamics. Further
advances include adjuvanted vaccines, and, in earlier development stages, DNA-
and universal vaccine candidates.
Reasons to Purchase
- Review the clinical and commercial factors driving new product decisions
in influenza vaccines and the strategies of key players in the market
- Gain insight through a patient-based forecast and a thorough analysis of
the seasonal and pandemic influenza vaccine pipeline
- Understand where concerns, unmet needs and future opportunities lie by
learning about the views of key influenza vaccine opinion leaders
| 
View Cart
